Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

 View HTML
0000912057-15-000045.pdf
0000912057-15-000045.rtf
0000912057-15-000045.xls
DRS/A

mendment to a previously filed DRS

 View HTML
0000912057-15-000057.pdf
0000912057-15-000057.rtf
0000912057-15-000057.xls
EFFECT

EFFECT

 View HTML
9999999995-15-001054.pdf
9999999995-15-001054.rtf
9999999995-15-001054.xls
EFFECT

EFFECT

 View HTML
9999999995-16-005229.pdf
9999999995-16-005229.rtf
9999999995-16-005229.xls
S-1

Registration statement for face-amount certificate companies

 View HTML
0001047469-15-002608.pdf
0001047469-15-002608.rtf
0001047469-15-002608.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003351.pdf
0001047469-15-003351.rtf
0001047469-15-003351.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001047469-15-003668.pdf
0001047469-15-003668.rtf
0001047469-15-003668.xls
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

 View HTML
0001104659-15-031752.pdf
0001104659-15-031752.rtf
0001104659-15-031752.xls
S-3

Simplified registration form

 View HTML
0001558370-16-005826.pdf
0001558370-16-005826.rtf
0001558370-16-005826.xls
S-3/A

Pre-effective amendment to an S-3 filing

 View HTML
0001558370-16-006734.pdf
0001558370-16-006734.rtf
0001558370-16-006734.xls